Last reviewed · How we verify
WST 11 -mediated -VTP
WST 11 -mediated -VTP is a Small molecule drug developed by Steba Biotech S.A.. It is currently in Phase 1 development. Also known as: TOOKAD Soluble.
WST 11 is used in a treatment called Vascular-Targeted Photodynamic Therapy (VTP) to study its safety and tolerability in patients with various cancers, including Prostate Cancer, Renal Cancer, and Esophagogastric Cancer. This treatment is also being studied for its potential to alleviate Moderate to Severe Dysphagia.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | WST 11 -mediated -VTP |
|---|---|
| Also known as | TOOKAD Soluble |
| Sponsor | Steba Biotech S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (PHASE1)
- Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer (PHASE1, PHASE2)
- Vascular Targeted Photodynamic Therapy T1a Renal Tumours (PHASE1, PHASE2)
- Study of WST11 in Patients With Localized Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WST 11 -mediated -VTP CI brief — competitive landscape report
- WST 11 -mediated -VTP updates RSS · CI watch RSS
- Steba Biotech S.A. portfolio CI
Frequently asked questions about WST 11 -mediated -VTP
What is WST 11 -mediated -VTP?
Who makes WST 11 -mediated -VTP?
Is WST 11 -mediated -VTP also known as anything else?
What development phase is WST 11 -mediated -VTP in?
Related
- Manufacturer: Steba Biotech S.A. — full pipeline
- Also known as: TOOKAD Soluble
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing